Event Overview

The roundtable, entitled "Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale," is organized by the Manufacturers Association of Israel. Mr. Reichman will be collaborating with senior representatives from the Manufacturers Association to facilitate an insightful discussion focused on Israel's biopharma development and manufacturing ecosystem. This session aims to provide a fact-based exploration of early-stage development, CMC activities, and clinical manufacturing.

Discussion Focus

Key topics to be covered include:

• Access to laboratory infrastructure
• CMC (Chemistry, Manufacturing, and Controls) and analytical capabilities
• GMP (Good Manufacturing Practice) manufacturing for clinical supply
• Challenges in early-stage development
• Readiness for later-stage and commercial manufacturing

These discussions are vital for shaping strategic decisions regarding regulatory readiness and investment in the biopharma sector. The roundtable will also evaluate local and international CDMOs (Contract Development and Manufacturing Organizations) and assess current manufacturing capabilities and collaboration opportunities across the ecosystem.

Industry Implications and Future Trends

Global trends influencing biopharma manufacturing will be a central point of discussion, particularly the increase in complexity of biologic modalities and formats, evolving regulatory expectations, and the expanding reliance on specialized CDMOs. Participants will evaluate how national manufacturing capabilities need to adapt to remain competitive over the next 5 to 10 years.

Mr. Reichman stated, "The Manufacturers Association plays a central role in shaping Israel's industrial capabilities." He emphasized that the session aims to pragmatically assess whether Israel possesses the necessary infrastructure to support biopharma companies from early clinical stages onward, and what actions are essential to reinforce this foundation.

Who Will Attend?

The roundtable is expected to attract a diverse group of stakeholders, including:

• Government representatives and public agency officials
• Israeli and international biopharma manufacturers
• CDMOs
• Multinational pharmaceutical companies
• Biotech firms with clinical and commercial expertise
• Investors familiar with biopharma development and manufacturing risks

HealthIL Week stands as Israel's premier international conference for healthcare innovation, uniting leaders from industry, academia, government, and the investment community to tackle current challenges in the healthcare and life sciences sectors.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) operates through two integral business units:

• Scinai Bioservices: A boutique CDMO that provides analytical method development, process development, and clinical cGMP manufacturing services to biotech clients globally.
• Scinai R&D: Focused on the development of innovative I&I therapeutics based on NanoAbs (VHH antibody fragments), designed with unique physicochemical properties suitable for advanced monoclonal and multispecific antibody formats.

To learn more about Scinai Immunotherapeutics, visit www.scinai.com.

Forward-Looking Statements

This article contains forward-looking statements as defined by the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," and similar expressions denote forward-looking statements. These statements reflect management's current views on certain events and are subject to various risks and uncertainties. More detailed information can be found in the company’s Annual Report on Form 20-F and subsequent filings with the SEC.